ATE247983T1 - Konjugate von einem interleukin-2 rezeptor spezifisch erkennenden faktor mit ribonuklease - Google Patents

Konjugate von einem interleukin-2 rezeptor spezifisch erkennenden faktor mit ribonuklease

Info

Publication number
ATE247983T1
ATE247983T1 AT97109034T AT97109034T ATE247983T1 AT E247983 T1 ATE247983 T1 AT E247983T1 AT 97109034 T AT97109034 T AT 97109034T AT 97109034 T AT97109034 T AT 97109034T AT E247983 T1 ATE247983 T1 AT E247983T1
Authority
AT
Austria
Prior art keywords
ribonuclease
interleukin
conjugates
specific recognition
receptor specific
Prior art date
Application number
AT97109034T
Other languages
English (en)
Inventor
Masakazu Ueda
Original Assignee
Daiichi Suntory Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Suntory Pharma Co Ltd filed Critical Daiichi Suntory Pharma Co Ltd
Application granted granted Critical
Publication of ATE247983T1 publication Critical patent/ATE247983T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
AT97109034T 1996-06-05 1997-06-04 Konjugate von einem interleukin-2 rezeptor spezifisch erkennenden faktor mit ribonuklease ATE247983T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8142485A JPH09324000A (ja) 1996-06-05 1996-06-05 インターロイキン−2受容体を特異的に認識する因子とリボヌクレアーゼとの接合体

Publications (1)

Publication Number Publication Date
ATE247983T1 true ATE247983T1 (de) 2003-09-15

Family

ID=15316427

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97109034T ATE247983T1 (de) 1996-06-05 1997-06-04 Konjugate von einem interleukin-2 rezeptor spezifisch erkennenden faktor mit ribonuklease

Country Status (4)

Country Link
EP (1) EP0811385B1 (de)
JP (1) JPH09324000A (de)
AT (1) ATE247983T1 (de)
DE (1) DE69724328T2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7325341B2 (ja) 2017-07-11 2023-08-14 シンソークス,インク. 非天然ヌクレオチドの組み込み及びその方法
KR20240141853A (ko) 2017-08-03 2024-09-27 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
EP3923974A4 (de) 2019-02-06 2023-02-08 Synthorx, Inc. Il-2-konjugate und verfahren zur verwendung davon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
GB9300686D0 (en) * 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting

Also Published As

Publication number Publication date
EP0811385A3 (de) 1998-05-13
DE69724328D1 (de) 2003-10-02
DE69724328T2 (de) 2004-08-19
JPH09324000A (ja) 1997-12-16
EP0811385A2 (de) 1997-12-10
EP0811385B1 (de) 2003-08-27

Similar Documents

Publication Publication Date Title
HU891055D0 (en) Ultrasonic contrast materials, process for their preparation and for their use as diagnostical and therapeutical drugs
ATE76747T1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
BR9303469A (pt) Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas
NL300353I1 (nl) Geneesmiddelen met monoclonale antilichamen, die specifiek zijn voor de menselijk epidermale groeifactorreceptor
FI905718A0 (fi) Transdermalt medel.
CA2149329A1 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
DE3776946D1 (de) Nasale verabreichung von arzneimitteln.
ZA909762B (en) Process for the production of biologically active protein
DE3770730D1 (de) Antikrebstherapie und zytotoxische arzneimittel fuer deren implementation.
DE59309858D1 (de) Geschmacksmaskierte pharmazeutische Mittel
EP0372752A3 (en) Cd4 polypeptide derivatives
IL138424A0 (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
FR2609632B1 (fr) Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
DE69006654D1 (de) Einen Zink-Komplex enthaltende Arzneimittel.
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
DE69004532D1 (de) Topisch anzuwendende Defibrotid enthaltende Arzneizubereitungen.
ATE247983T1 (de) Konjugate von einem interleukin-2 rezeptor spezifisch erkennenden faktor mit ribonuklease
DK0559145T3 (da) Lægemiddel til truende abort
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
AU2229997A (en) Pharmaceutical compositions comprising natural human alpha-interferon
PT91571A (pt) Verfahren fuer die herstellung von phyto und zoosterole und deren derivate mit verbesserter wasseroeslichkeit
DE59107240D1 (de) Emulgatorfreie Emulsionspolymere in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe und ihre Herstellung
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
AU8501191A (en) Cross-reactive influenza a immunization
NO890261D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydropyridin-derivater.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties